NCT06736587View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Autoimmune Diseases
Interventions
DRUG

DWP212525 10mg

DWP212525 10mg

DRUG

DWP212525 30mg

DWP212525 30mg

DRUG

DWP212525 50mg

DWP212525 50mg

DRUG

DWP212525 100mg

DWP212525 100mg

DRUG

DWP212525 200mg

DWP212525 200mg

DRUG

DWP212525 400mg

DWP212525 400mg

DRUG

DWP212525 placebo

DWP212525 placebo

Trial Locations (1)

03080

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY